Martin Shkreli is the founder and CEO of Turing Pharmaceuticals. He is the founder of Retrophin, LLC (the predecessor of Retrophin, Inc.) and former President of Retrophin, Inc. since its formation. Martin Shkreli is also the founder and managing partner of MSMB Capital Management, a New York hedge fund firm founded in 2006 that manages a variety of partnerships. Prior to MSMB, Martin Shkreli was employed at Intrepid Capital Management from 2004 to 2006 and previously at Cramer Berkowitz & Co, both of which are hedge fund firms based in New York. Martin Shkreli is an experienced biotechnology and pharmaceutical industry investor, particularly in businesses with orphan drugs. Martin Shkreli received his BBA from Baruch College.